Patents by Inventor Jason D. Speake
Jason D. Speake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11691992Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.Type: GrantFiled: February 11, 2021Date of Patent: July 4, 2023Assignees: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretary of the ArmyInventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
-
Patent number: 11512088Abstract: The present disclosure describes a synthetic process and novel intermediates related to spirocyclic azetidenyl-isobenzofuran derivatives having an isothiazoline moiety, which are useful as antiparasitics.Type: GrantFiled: January 29, 2020Date of Patent: November 29, 2022Assignee: AVISTA PHARMA SOLUTIONS, INC.Inventors: Jason D. Speake, Joe B. Perales, Brent Christopher Beck, Bharathi Pandi
-
Patent number: 11459331Abstract: The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of the disclosure, which are EP4 receptor antagonists.Type: GrantFiled: January 29, 2020Date of Patent: October 4, 2022Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Brent Christopher Beck, Bharathi Pandi, Jennifer C. Freeman
-
Patent number: 11220507Abstract: The present invention relates to a process for the preparation of rucaparib; the invention also refers to novel intermediates of synthesis as well as their use in the preparation of i.a. rucaparib.Type: GrantFiled: December 15, 2017Date of Patent: January 11, 2022Assignee: Advitech Advisory and Technologies SAInventors: Brent Christopher Beck, Joe B. Perales, Jason D. Speake, Ilaria Ferrando
-
Publication number: 20210253605Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.Type: ApplicationFiled: February 11, 2021Publication date: August 19, 2021Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
-
Patent number: 10961261Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.Type: GrantFiled: March 1, 2018Date of Patent: March 30, 2021Assignees: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretaryof the ArmyInventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
-
Patent number: 10807992Abstract: The present invention relates to single enantiomer isothiazoline compounds of formula (I): and methods of synthesizing the compounds. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: GrantFiled: November 15, 2018Date of Patent: October 20, 2020Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Bakela Nare, Joe B. Perales, Keqiang Li, Cisco Bee, Jeffrey A. Adams, Kurt S. Van Horn, Brian H. Heasley
-
Patent number: 10772331Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: GrantFiled: May 23, 2019Date of Patent: September 15, 2020Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Joe B. Perales, Weiming Fan, Solene Clarisse Rolland
-
Publication number: 20200270257Abstract: The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of the disclosure, which are EP4 receptor antagonists.Type: ApplicationFiled: January 29, 2020Publication date: August 27, 2020Inventors: Jason D. Speake, Brent Christopher BECK, Bharathi PANDI, Jennifer C. FREEMAN
-
Patent number: 10744136Abstract: The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus Kinase inhibitors and are useful in the treatment or control of pruritus, associated with allergic dermatitis, atopic dermatitis in animals, and other disorders and indications where immunosuppression/immunomodulation would be desirable. Also described herein are methods of treating pruritus and atopic dermatitis by administering the compounds of the invention, which are JAK 1 inhibitors.Type: GrantFiled: November 4, 2019Date of Patent: August 18, 2020Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Bharathi Pandi, Joe B. Perales, Weiming Fan
-
Publication number: 20200239481Abstract: The present disclosure describes a synthetic process and novel intermediates related to spirocyclic azetidenyl-isobenzofuran derivatives having an isothiazoline moiety, which are useful as antiparasitics.Type: ApplicationFiled: January 29, 2020Publication date: July 30, 2020Inventors: Jason D. Speake, Joe B. PERALES, Brent Christopher BECK, Bharathi PANDI
-
Publication number: 20200181134Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: ApplicationFiled: July 7, 2017Publication date: June 11, 2020Inventor: Jason D. Speake
-
Patent number: 10570144Abstract: The present invention describes compounds of Formula (I): or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of Formula (I) have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of Formula (I), which are EP4 receptor antagonists.Type: GrantFiled: January 31, 2019Date of Patent: February 25, 2020Assignee: Avista Pharma Solutions, Inc.Inventor: Jason D. Speake
-
Patent number: 10556909Abstract: The present disclosure describes a synthetic process and novel intermediates related to spirocyclic azetidenyl-isobenzofuran derivatives having an isothiazoline moiety, which are useful as antiparasitics.Type: GrantFiled: May 17, 2017Date of Patent: February 11, 2020Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Bharathi Pandi, Cyprian O. Ogbu, Jeffrey A. Adams, Joseph A. Moore, III, Joe B. Perales, Keqiang Li
-
Publication number: 20200024289Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.Type: ApplicationFiled: March 1, 2018Publication date: January 23, 2020Applicants: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretary of the Army, The Government of the United States, as represented by the Secretary of the ArmyInventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
-
Publication number: 20190284199Abstract: The present disclosure describes a synthetic process and novel intermediates related to spirocyclic azetidenyl-isobenzofuran derivatives having an isothiazoline moiety, which are useful as antiparasitics.Type: ApplicationFiled: May 17, 2017Publication date: September 19, 2019Inventors: Jason D Speake, Bharathi Pandi, Cyprian O. Ogbu, Jeffrey A. Adams, Joseph A. Moore, III, Joe B. Perales, Keqiang Li
-
Publication number: 20190274305Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: ApplicationFiled: May 23, 2019Publication date: September 12, 2019Inventors: Jason D. Speake, Joe B. Perales, Weiming Fan, Solene Clarisse Rolland
-
Patent number: 10342234Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: GrantFiled: September 6, 2018Date of Patent: July 9, 2019Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Joe B. Perales, Weiming Fan, Solene Clarisse Rolland
-
Publication number: 20190152983Abstract: The present invention relates to single enantiomer isothiazoline compounds of formula (I) and methods of synthesizing the compounds. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: ApplicationFiled: November 15, 2018Publication date: May 23, 2019Inventors: Jason D. Speake, Bakela Nare, Joe B. Perales, Keqiang Li, Cisco Bee, Jeffrey A. Adams, Kurt S. Van Horn, Brian H. Heasley
-
Patent number: 10239885Abstract: The present invention describes novel compounds, or veterinary or pharmaceutically acceptable salts thereof, veterinary or pharmaceutical compositions thereof, and medical uses thereof. The compounds of the invention have activity as prostaglandin EP4 receptor antagonists and are useful in the treatment or alleviation of pain, inflammation and inflammation-associated disorders. Also described herein are methods for treating pain by administering the compounds of the invention. For example, the invention describes 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-a]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyflurea of the formula: veterinary or pharmaceutical compositions thereof, and methods of treatment using the subject compound and compositions thereof.Type: GrantFiled: August 10, 2018Date of Patent: March 26, 2019Assignee: Avista Pharma Solutions, Inc.Inventor: Jason D. Speake